Dementia (Central Nervous System) – Drugs In Development, 2021

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Dementia (Central Nervous System) – Drugs In Development, 2021, provides an overview of the Dementia (Central Nervous System) pipeline landscape.

Dementia is the loss of mental functions such as thinking, memory, and reasoning that is severe enough to interfere with a person's daily functioning. Symptoms include memory loss, hallucinations, agitation, personality changes and difficulty with coordination and motor functions. Risk factors include age, smoking, obesity, high blood pressure, inflammation and cardiovascular diseases.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Dementia (Central Nervous System) – Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Dementia (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Dementia (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Dementia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 1, 13, 35, 31, 2, 79, 41 and 2 respectively. Similarly, the Universities portfolio in Preclinical, Discovery and Unknown stages comprises 13, 5 and 1 molecules, respectively.

Dementia (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

– The pipeline guide provides a snapshot of the global therapeutic landscape of Dementia (Central Nervous System).

– The pipeline guide reviews pipeline therapeutics for Dementia (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.

– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

– The pipeline guide reviews key companies involved in Dementia (Central Nervous System) therapeutics and enlists all their major and minor projects.

– The pipeline guide evaluates Dementia (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

– The pipeline guide reviews latest news related to pipeline therapeutics for Dementia (Central Nervous System)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Dementia (Central Nervous System).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Dementia (Central Nervous System) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies mentioned

AbbVie Inc

Acadia Pharmaceuticals Inc

Actinogen Medical Ltd

AcuraStem Inc

Adamed Sp zoo

ADEL Inc

AFFiRiS AG

AgeneBio Inc

AIBIOS Co Ltd

Alector Inc

Alkermes Plc

AlphaCognition Inc

Alterity Therapeutics Ltd

Amarantus Bioscience Holdings Inc

Anavex Life Sciences Corp

Annovis Bio Inc

Aphios Corp

Applied Genetic Technologies Corp

Aprinoia Therapeutics Inc

Aptinyx Inc

AriBio

Arkuda Therapeutics Inc

IntraBio Ltd

Inventage Lab Inc

IRLAB Therapeutics AB

Jazz Pharmaceuticals Plc

Johnson & Johnson

KeifeRx LLC

Kogenix Therapeutics Inc

Korea Pharma Co Ltd

Kwang Dong Pharmaceutical Co Ltd

Lachesis Biosciences Ltd

Locanabio Inc

Whan In Pharm Co Ltd

Yumanity Therapeutics

Yumanity Therapeutics Inc

Table of Contents

Table of Contents

Introduction

Dementia - Overview

Dementia - Therapeutics Development

Dementia - Therapeutics Assessment

Dementia - Companies Involved in Therapeutics Development

Dementia - Drug Profiles

Dementia - Dormant Projects

Dementia - Discontinued Products

Dementia - Product Development Milestones

Appendix

List of Tables

List of Tables

Number of Products under Development for Dementia, 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Universities/Institutes, 2021

Products under Development by Companies, 2021

Products under Development by Universities/Institutes, 2021

Number of Products by Stage and Target, 2021

Number of Products by Stage and Mechanism of Action, 2021

Number of Products by Stage and Route of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

Dementia – Pipeline by AbbVie Inc, 2021

Dementia – Pipeline by Acadia Pharmaceuticals Inc, 2021

Dementia – Pipeline by Actinogen Medical Ltd, 2021

Dementia – Pipeline by AcuraStem Inc, 2021

Dementia – Pipeline by Adamed Sp zoo, 2021

Dementia – Pipeline by ADEL Inc, 2021

Dementia – Pipeline by AFFiRiS AG, 2021

Dementia – Pipeline by AgeneBio Inc, 2021

Dementia – Pipeline by AIBIOS Co Ltd, 2021

Dementia – Pipeline by Alector Inc, 2021

Dementia – Pipeline by Alkermes Plc, 2021

Dementia – Pipeline by AlphaCognition Inc, 2021

Dementia – Pipeline by Alterity Therapeutics Ltd, 2021

Dementia – Pipeline by Amarantus Bioscience Holdings Inc, 2021

Dementia – Pipeline by Anavex Life Sciences Corp, 2021

Dementia – Pipeline by Annovis Bio Inc, 2021

Dementia – Pipeline by Aphios Corp, 2021

Dementia – Pipeline by Dr. August Wolff GmbH & Co KG Arzneimittel, 2021

Dementia – Pipeline by Yumanity Therapeutics Inc, 2021

Dementia – Dormant Projects, 2021

Dementia – Discontinued Products, 2021

List of Figures

List of Figures

Number of Products under Development for Dementia, 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Universities/Institutes, 2021

Number of Products by Top 10 Targets, 2021

Number of Products by Stage and Top 10 Targets, 2021

Number of Products by Top 10 Mechanism of Actions, 2021

Number of Products by Stage and Top 10 Mechanism of Actions, 2021

Number of Products by Top 10 Routes of Administration, 2021

Number of Products by Stage and Top 10 Routes of Administration, 2021

Number of Products by Top 10 Molecule Types, 2021

Number of Products by Stage and Top 10 Molecule Types, 2021

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports